{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:34:17Z","timestamp":1771263257736,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Some infants undergoing newborn screening (NBS) tests have inconclusive sweat chloride test (SCT) results that lead to the designation of Cystic Fibrosis Screen Positive, Inconclusive Diagnosis\/CFTR-related metabolic syndrome (CFSPID\/CRMS). Some proportion of them transition to a CF diagnosis, but no predictive markers can stratify which are at risk for this transition. We report single-center outcomes of children with CRMS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively identified all infants born in Alabama from 2008 through 2020 referred to our CF Center with an elevated immunoreactive trypsinogen level (IRT) associated with a cystic fibrosis transmembrane conductance regulator (CFTR) mutation (IRT+\/DNA+) who had at least one SCT result documented. Infants were classified per established guidelines as Carrier, CRMS, or CF based on the IRT+\/DNA+ and SCT results. The electronic health record was reviewed for follow-up visits until the children received a definitive diagnosis (to carrier or CF) according to current diagnostic guidelines for CF, or through the end of the 2020 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 1,346 infants with IRT+ and at least 1 CFTR mutation identified (IRT+\/DNA+), 63 (4.7%) were designated as CRMS. Of these infants, 12 (19.1%) transitioned to Carrier status (CRMS-Carrier), 40 (63.5%) of them remained CRMS status (CRMS-Persistent) and 11 (17.5%) of them transitioned to a diagnosis of CF (CRMS-CF). Of the 11 children in the CRMS-CF group, 4 (36%) had an initial SCT 30\u201339\u2005mmol\/L, 4 (36%) had an initial SCT 40\u201349\u2005mmol\/L and 3 (27%) had an initial SCT 50\u201359\u2005mmol\/L. These children also had higher initial sweat tests and greater yearly increases in sweat chloride values than others with CRMS. We found that in comparison to children in the CRMS-<jats:italic>P<\/jats:italic> group, a greater proportion of children in the CRMS-CF group cultured bacteria like methicillin-resistant <jats:italic>Staphylococcus aureus, Stenotrophomonas maltophilia, and Pseudomonas aeruginosa,<\/jats:italic> had smaller weight-for-height percentiles and remained smaller over time despite slightly greater growth.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Infants with an inconclusive diagnosis of CF should continue to receive annual care and management given their potential risk of transition to CF. Further research is needed to assess whether certain phenotypic patterns, clinical symptoms, diagnostic tests or biomarkers could better stratify these children.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1127659","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T06:08:45Z","timestamp":1678342125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis\/CFTR related metabolic syndrome"],"prefix":"10.3389","volume":"11","author":[{"given":"Mohini A.","family":"Gunnett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Mims","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staci T.","family":"Self","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector H.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Guimbellot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1542\/pir.30.8.302","article-title":"Cystic fibrosis","volume":"30","author":"Montgomery","year":"2009","journal-title":"Pediatr Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-2600(16)00053-9","article-title":"Newborn screening for cystic fibrosis","volume":"4","author":"Castellani","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/archdischild-2011-300449","article-title":"Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre","volume":"96","author":"Dijk","year":"2011","journal-title":"Arch Dis Child"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jpeds.2016.09.065","article-title":"Diagnosis of cystic fibrosis in screened populations","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1542\/peds.2014-3698","article-title":"Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis\u00a0newborn screening","volume":"135","author":"Ren","year":"2015","journal-title":"Pediatrics"},{"key":"B6","year":""},{"key":"B7","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.04.020","article-title":"Clinical outcomes of a large cohort of individuals with the F508del\/5\u2005T;TG12 CFTR genotype","author":"Tosco","year":"2022","journal-title":"J Cyst Fibros"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.07.007","article-title":"Different management approaches and outcome for infants with an inconclusive diagnosis following newborn screening for cystic fibrosis (CRMS\/CFSPID) and Pseudomonas aeruginosa isolation","author":"Dolce","year":"2022","journal-title":"J Cyst Fibros"},{"key":"B10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jcf.2021.03.015","article-title":"A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS\/CFSPID) in six Italian centres","volume":"20","author":"Terlizzi","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1002\/ppul.25683","article-title":"Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/CF screen-positive, inconclusive diagnosis","volume":"56","author":"Terlizzi","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"210088","DOI":"10.1183\/20734735.0088-2021","article-title":"Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/cystic fibrosis screen positive, inconclusive diagnosis (CRMS\/CFSPID)","volume":"17","author":"Sinha","year":"2021","journal-title":"Breathe (Sheff)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcf.2020.11.006","article-title":"Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/cystic fibrosis screen positive, inconclusive diagnosis (CRMS\/CFSPID)","volume":"20","author":"Barben","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijns6010019","article-title":"Inconclusive diagnosis after newborn screening for cystic fibrosis","volume":"6","author":"Munck","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/ppul.25296","article-title":"Outcomes of repeat sweat testing in cystic fibrosis newborn screen positive infants","volume":"56","author":"Bauer","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-051740","article-title":"Outcomes of cystic fibrosis screening-positive infants with inconclusive diagnosis at school age","volume":"148","author":"Gonska","year":"2021","journal-title":"Pediatrics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1377","DOI":"10.1542\/peds.2014-2081","article-title":"Inconclusive diagnosis of cystic fibrosis after newborn screening","volume":"135","author":"Ooi","year":"2015","journal-title":"Pediatrics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/cge.12711","article-title":"Refining the continuum of CFTR-associated disorders in the era of newborn screening","volume":"89","author":"Levy","year":"2016","journal-title":"Clin Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1542\/peds.2015-0811","article-title":"Newborn screening for cystic fibrosis in California","volume":"136","author":"Kharrazi","year":"2015","journal-title":"Pediatrics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jpeds.2015.01.052","article-title":"Long-term outcomes of children with intermediate sweat chloride values in infancy","volume":"166","author":"Groves","year":"2015","journal-title":"J Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/ppul.24721","article-title":"Trend of sweat chloride values in a cohort of patients carrying CFTR mutations of varying clinical consequence: is there a risk of increasing sweat chloride over time?","volume":"55","author":"Terlizzi","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jcf.2019.04.010","article-title":"Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition","volume":"18","author":"Southern","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B23","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ppul.24634","article-title":"Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening","volume":"55","author":"Munck","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.jcf.2021.06.012","article-title":"When CFSPID becomes CF","volume":"21","author":"Ginsburg","year":"2022","journal-title":"J Cyst Fibros"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jpeds.2016.09.063","article-title":"Applying cystic fibrosis transmembrane conductance regulator genetics and CFTR2 data to facilitate diagnoses","volume":"181","author":"Sosnay","year":"2017","journal-title":"J Pediatr"},{"key":"B26","year":""},{"key":"B27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12887-019-1756-4","article-title":"Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis","volume":"19","author":"Ooi","year":"2019","journal-title":"BMC Pediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1055\/s-0035-1547318","article-title":"Genotypes and phenotypes in cystic fibrosis and cystic fibrosis transmembrane regulator-related disorders","volume":"36","author":"Bombieri","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.jpeds.2009.09.003","article-title":"Cystic fibrosis foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond","volume":"155","author":"Borowitz","year":"2009","journal-title":"J Pediatr"},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ijns6020025","article-title":"Processing newborn bloodspot screening results for CF","volume":"6","author":"Barben","year":"2020","journal-title":"Int J Neonatal Screen"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1127659\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T06:08:49Z","timestamp":1678342129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1127659\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":30,"alternative-id":["10.3389\/fped.2023.1127659"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1127659","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"article-number":"1127659"}}